TY - JOUR
T1 - Longitudinal examination of fellow-eye vascular anomalies in coats’ disease with widefield fluorescein angiography
T2 - A multicenter study
AU - Jeng-Miller, Karen W.
AU - Soomro, Taha
AU - Scott, Nathan L.
AU - Rao, Prethy
AU - Marlow, Elizabeth
AU - Chang, Emmanuel Y.
AU - Ells, Anna
AU - Chau, Felix
AU - Nudleman, Eric
AU - Calvo, Charles M.
AU - Patel, Nish
AU - Schwartz, Roy
AU - Cernichiaro-Espinosa, Linda A.
AU - Montoya, Alexandrea Gabrielle
AU - Goldstein, Jessica
AU - Harper, C. Armitage
AU - Baumal, Caroline R.
AU - Hartnett, Mary Elizabeth
AU - Harbour, J. William
AU - Besirli, Cagri G.
AU - Gupta, Mrinali P.
AU - Chan, R. V.Paul
AU - Drenser, Kimberly A.
AU - Capone, Antonio
AU - Murray, Timothy G.
AU - Mukai, Shizuo
AU - Trese, Michael T.
AU - Berrocal, Audina M.
AU - Wong, Sui Chien
AU - Yonekawa, Yoshihiro
N1 - Funding Information:
Originally submitted June 15, 2018. Revision received August 16, 2018. Accepted for publication November 5, 2018. This manuscript was presented at The Retina Society 2017 Annual Meeting, Boston, October 5-8, 2017. This study was funded by unrestricted grants from Research to Prevent Blindness to the Illinois Eye and Ear Infirmary, University of Illinois (RVPC); an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology, New York-Presbyterian Hospital, Weill Cornell Medical College (MPG); grants from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences at the University of Utah, John A. Moran Eye Center; NEI R01EY015130 and R01EY017011 (MEH); Children’s Hospital Ophthalmology Foundation (YY); Mukai Fund of the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts (SM); Yonekawa Research Fund, Mass Eye & Ear (YY). The funding organizations played no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. Dr. Mukai is a consultant to Boehringer-Ingelheim. Dr. Chang has received funding from Allergan. Dr. Gupta has received funding from Alcon, Allergan, Genentech, and Regeneron. Dr. Nudleman has received funding from Alcon, Allergan, and Visunex. Dr. Trese has received funding from FocusROP and Phoenix Clinical. Dr. Yonekawa is on the advisory board for Alcon, Alimera, Allergan, and Regeneron and has received honorarium from Optos. The remaining authors report no relevant financial disclosures. Address correspondence to Yoshihiro Yonekawa, MD, 243 Charles Street, Boston, MA 02114; email: yoshihiro_yonekawa@meei.harvard.edu. doi: 10.3928/23258160-20190401-04
Funding Information:
This study was funded by unrestricted grants from Research to Prevent Blindness to the Illinois Eye and Ear Infirmary, University of Illinois (RVPC); an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology, New York-Presbyterian Hospital, Weill Cornell Medical College (MPG); grants from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences at the University of Utah, John A. Moran Eye Center; NEI R01EY015130 and R01EY017011 (MEH); Children?s Hospital Ophthalmology Foundation (YY); Mukai Fund of the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts (SM); Yonekawa Research Fund, Mass Eye & Ear (YY). The funding organizations played no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2019 Slack Incorporated. All rights reserved.
PY - 2019
Y1 - 2019
N2 - BACKGROUND AND OBJECTIVE: Retinovascular anomalies in the fellow eyes of patients with Coats’ disease have been described, but the clinical significance is unknown, as well as whether these lesions progress over time. PATIENTS AND METHODS: This is an international, multicenter, retrospective, observational cohort study of fellow-eye abnormalities on widefield fluorescein angiography in patients with Coats’ disease. RESULTS: Three hundred fifty eyes of 175 patients with Coats’ disease were analyzed. A total of 33 patients (18.8%) demonstrated abnormal fellow-eye findings: 14 (42.4%) telangiectasias, 18 (54.5%) aneurysms, six (18.2%) segmental non-perfusion, six (18.2%) leakage, and two (6.0%) vascular tortuosity. All eyes were asymptomatic, and none of the lesions progressed over time. There was no association between fellow-eye findings with severity of Coats’ disease (P = .16), patient age (P = .16), or presence of systemic vascular disease (P = .16). CONCLUSIONS: The vascular abnormalities in fellow eyes of patients with Coats’ disease did not progress over time. Observation is a reasonable initial management strategy.
AB - BACKGROUND AND OBJECTIVE: Retinovascular anomalies in the fellow eyes of patients with Coats’ disease have been described, but the clinical significance is unknown, as well as whether these lesions progress over time. PATIENTS AND METHODS: This is an international, multicenter, retrospective, observational cohort study of fellow-eye abnormalities on widefield fluorescein angiography in patients with Coats’ disease. RESULTS: Three hundred fifty eyes of 175 patients with Coats’ disease were analyzed. A total of 33 patients (18.8%) demonstrated abnormal fellow-eye findings: 14 (42.4%) telangiectasias, 18 (54.5%) aneurysms, six (18.2%) segmental non-perfusion, six (18.2%) leakage, and two (6.0%) vascular tortuosity. All eyes were asymptomatic, and none of the lesions progressed over time. There was no association between fellow-eye findings with severity of Coats’ disease (P = .16), patient age (P = .16), or presence of systemic vascular disease (P = .16). CONCLUSIONS: The vascular abnormalities in fellow eyes of patients with Coats’ disease did not progress over time. Observation is a reasonable initial management strategy.
UR - http://www.scopus.com/inward/record.url?scp=85065098864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065098864&partnerID=8YFLogxK
U2 - 10.3928/23258160-20190401-04
DO - 10.3928/23258160-20190401-04
M3 - Article
C2 - 30998243
AN - SCOPUS:85065098864
VL - 50
SP - 221
EP - 227
JO - Ophthalmic surgery, lasers & imaging retina
JF - Ophthalmic surgery, lasers & imaging retina
SN - 2325-8160
IS - 4
ER -